Linda Sciuto
Overview
Explore the profile of Linda Sciuto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
341
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Desai P, Takahashi N, Kumar R, Nichols S, Malin J, Hunt A, et al.
Cell Rep Med
. 2024 Jun;
5(6):101610.
PMID: 38897168
Small-cell lung cancer (SCLC) is the most fatal form of lung cancer. Intratumoral heterogeneity, marked by neuroendocrine (NE) and non-neuroendocrine (non-NE) cell states, defines SCLC, but the cell-extrinsic drivers of...
2.
Takahashi N, Hao Z, Villaruz L, Zhang J, Ruiz J, Petty W, et al.
JAMA Oncol
. 2023 Oct;
9(12):1669-1677.
PMID: 37824137
Importance: Patients with relapsed small cell lung cancer (SCLC), a high replication stress tumor, have poor prognoses and few therapeutic options. A phase 2 study showed antitumor activity with the...
3.
Abel M, Takahashi N, Peer C, Redon C, Nichols S, Vilimas R, et al.
Clin Cancer Res
. 2023 May;
29(18):3603-3611.
PMID: 37227187
Purpose: Despite promising preclinical studies, toxicities have precluded combinations of chemotherapy and DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted chemotherapy delivery might enable clinical translation of such combinations....
4.
Pongor L, Schultz C, Rinaldi L, Wangsa D, Redon C, Takahashi N, et al.
Cancer Discov
. 2023 Jan;
13(4):928-949.
PMID: 36715552
Significance: MYC drives SCLC progression, but the genetic basis of MYC-driven SCLC evolution is unknown. Using SCLC as a paradigm, we report how ecDNA amplifications function as MYC-amplifying units, fostering...
5.
Thomas A, Fontaine S, Diolaiti M, Desai P, Kumar R, Takahashi N, et al.
Mol Cancer Ther
. 2022 Aug;
21(11):1722-1728.
PMID: 35999657
Alterations in the ATM gene are among the most common somatic and hereditary cancer mutations, and ATM-deficient tumors are hypersensitive to DNA-damaging agents. A synthetic lethal combination of DNA-damaging agents...
6.
Lissa D, Takahashi N, Desai P, Manukyan I, Schultz C, Rajapakse V, et al.
Nat Commun
. 2022 Apr;
13(1):2023.
PMID: 35440132
Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The...
7.
Thomas A, Takahashi N, Rajapakse V, Zhang X, Sun Y, Ceribelli M, et al.
Cancer Cell
. 2021 Apr;
39(4):566-579.e7.
PMID: 33848478
Small cell neuroendocrine cancers (SCNCs) are recalcitrant cancers arising from diverse primary sites that lack effective treatments. Using chemical genetic screens, we identified inhibition of ataxia telangiectasia and rad3 related...
8.
Tlemsani C, Takahashi N, Pongor L, Rajapakse V, Tyagi M, Wen X, et al.
Sci Transl Med
. 2021 Jan;
13(578).
PMID: 33504652
Because tobacco is a potent carcinogen, secondary causes of lung cancer are often diminished in perceived importance. To assess the extent of inherited susceptibility to small cell lung cancer (SCLC),...
9.
Schmidt K, Huitema A, Dorlo T, Peer C, Cordes L, Sciuto L, et al.
Cancer Chemother Pharmacol
. 2020 Sep;
86(4):475-486.
PMID: 32897402
Purpose: NLG207 (formerly CRLX101) is a nanoparticle-drug conjugate (NDC) of the potent topoisomerase I inhibitor, camptothecin (CPT). The present study sought to characterize the complex pharmacokinetics (PK) of NLG207 and...
10.
Thomas A, Redon C, Sciuto L, Padiernos E, Ji J, Lee M, et al.
J Clin Oncol
. 2017 Dec;
36(16):1594-1602.
PMID: 29252124
Purpose Our preclinical work identified depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and showed that ATR inhibition sensitizes tumors to TOP1 inhibitors. We...